Options in the management of essential thrombocythaemia

European Journal of Haematology

Volumn 79, Issue SUPPL. 68, 2007, Pages 35-39

  Griesshammer, Martin ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Anagrelide; Blood platelets; Essential thrombocythaemia; Hydroxyurea; Interferon; Leukaemia; Myeloproliferative disorders; Risk assessment; Thrombosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; INTERFERON; JANUS KINASE 2; PEGINTERFERON;

AGE DISTRIBUTION; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA; LONG TERM CARE; LOW DRUG DOSE; MYELOPROLIFERATIVE DISORDER; PATIENT CARE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; X CHROMOSOME;

EID: 34548202646     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00943.x     Document Type: Conference Paper

References (27)

1. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythaemia. A statement from the Italian Society of Haematology, the Italian Society of Experimental Haematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004 89 : 215 32.
2. Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythaemia. Semin Thromb Haemost 2006 32 : 372 80.
3. Michiels JJ, De RH, Berneman Z, Van BD, Hebeda K, Lam K, Schroyens W. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Haemost 2006 32 : 307 40.
4. Lahuerta-Palacios JJ, Bornstein R, Fernandez-Debora FJ, Gutierrez-Rivas E, Ortiz MC, Larregla S, Calandre L, Montero-Castillo J. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythaemia. Cancer 1988 61 : 1207 12.
5. Pearson TC. The risk of thrombosis in essential thrombocythaemia and polycythaemia vera. Semin Oncol 2002 29 : 16 21.
6. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998 100 : 15 23.
7. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythaemia with relatively low platelet counts. Am J Haematol 1997 56 : 168 72.
8. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 1994 23 : 73 7.
9. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythaemia. Blood 2001 97 : 863 6.
10. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythaemia and a high risk of thrombosis. N Engl J Med 1995 332 : 1132 6.
11. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythaemia and polycythaemia vera according to JAK2 V617F mutation status. Haematologica 2007 92 : 135 6.
12. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. J Clin Oncol 1990 8 : 556 62.
13. Schwarz J, Pytlik R, Doubek M, Brychtova Y, Dulicek P, Campr V, Kren L, Penka M. Analysis of risk factors: the rationale of the guidelines of the Czech Haematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythaemia 2. Semin Thromb Haemost 2006 32 : 231 45.
14. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993 83 : 198 203.
15. Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN, Kuo MC, Lee LC. Predictive values of X-chromosome inactivation patterns and clinicohaematologic parameters for vascular complications in female patients with essential thrombocythaemia. Blood 2002 100 : 1596 601.
16. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythaemia. Ann Haematol 2001 80 : 74 8.
17. Jensen MK, de Nully BP, Thorsen S, Hasselbalch HC. Frequent occurrence of anti-cardiolipin antibodies, Factor V Leiden mutation and perturbed endothelial function in chronic myeloproliferative disorders. Am J Haematol 2002 69 : 185 91.
18. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thrombo-embolism in polycythaemia vera and essential thrombocythaemia. Am J Haematol 2002 71 : 1 6.
19. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythaemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999 93 : 417 24.
20. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005 366 : 1945 53.
21. Vannuchhi AM, Barosi G, Rambaldi A, Marchioli R, Barbui T, for the GIMEMA MPD WP. Clinical significance of JAK2V617F homozygosity in the chronic myeloprofilerative disorders. A study on 1306 patients. Blood 2006 108 : 664.
22. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998 103 : 772 7.
23. Barbui T, Finazzi G. When and how to treat essential thrombocythaemia 2. N Engl J Med 2005 353 : 85 6.
24. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythaemia. N Engl J Med 2005 353 : 33 45.
25. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythaemia. Leuk Lymphoma 1996 22 (Suppl. 1 135 42.
26. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H, Schauer S, Gisslinger H, Griesshammer M. Pegylated interferon for the treatment of high risk essential thrombocythaemia: results of a phase II study. Haematologica 2005 90 : 1333 8.
27. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukaemogenic potential in myeloproliferative disorders. Leuk Res 2005 29 : 481 91.